|
| |
| | Cardiomyopathy as a Late Effect of... - Association of Pediatric Oncology Nurses |
 | | While there is a clear association between the development of cardiomyopathy and treatment with anthracycline chemotherapy, there are a variety of risk factors that influence the actual incidence of cardiomyopathy. | | | Thus, cardiac monitoring is imperative not only while the patient is receiving anthracycline therapy, but for years afterward. | | | Survival rates for children and adolescents treated for childhood cancer have improved due to advances in chemotherapy, radiation therapy, surgical intervention, and supportive care. |
|
http://www.apon.org/i4a/pages/Index.cfm?pageid=357
|
|
| |
| | Haema/Áßìá |
| | The theory, though, that histamine plays a role in anthracyclines cardiac lesions is not supported by the fact that in other conditions, where there is increased exposure to histamine, such as in anaphylactoid reactions or in mastocytosis, there are no cardiotoxic effects similar to those from anthracyclines. | | | Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. | | | The mechanism of anthracyclines cardiotoxicity is different from the mechanism of their antineoplastic activity as derived from preclinical data as well as from the clinical experience with the cardioprotectant dexrazoxane |
|
http://www.mednet.gr/eae/haema/h14-1.htm
|
|
| |
| | DG DISPATCH - BREAST CANCER: Anthracycline Superior To Cyclophosphamide/Methotextrate/5FU |
| | Additionally, 15 percent of patients on anthracycline experienced mucositis compared with six percent of patients on CMF. | | | Nearly two-thirds of patients in the anthracycline group experienced alopecia compared to 24 percent in the CMF group. | | | By contrast, 18 patients out of 21 (86 percent) who received anthracycline experienced a complete response, a figure that was statistically significant. |
|
http://www.pslgroup.com/dg/11b496.htm
|
|
| |
| | Thesis_1 |
| | Anthracycline targeting seems to be one realistic possibility, but in spite of early optimism, this approach has proved extremely difficult. | | | There is no doubt, however, that the anthracyclines will be the drugs of choice for some while yet, but much more basic research is required before we truly understand how they function in the growing tumor and how new derivatives with improved therapeutic properties can be synthesized. | | | In particular, the iron-dependent generation of reactive free radicals as an explanation of anthracycline cardiotoxicity continues to be controversial and is rejected by many researchers. |
|
http://home19.inet.tele.dk/bios/thesis/thesis_dsc/thesis_dsc.htm
|
|
| |
| | anthracycline |
| | In clinical trials, the incidence and severity of cardiac dysfunction was highest in patients receiving Herceptin with anthracycline and cyclophosphamide (AC). | | | Prior therapy should have included an anthracycline unless clinically contraindicated. | | | Annamycin, a drug from the anthracycline family, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced... |
|
http://www.cancer-help.org/cancer/0604/anthracycline.html
|
|
| |
| | British Journal of Pharmacology - Impairment of myocardial contractility by anticancer anthracyclines: role of ... |
| | Where indicated, NADPH-dependent conversion of anthracyclines to secondary alcohol metabolites was assayed in cytosolic fractions of human myocardial samples, precisely as reported ( Licata et al., 2000 ; Minotti et al., 2000). | | | This study lends support to the concept that secondary alcohol metabolites may be important determinants of cardiotoxicity induced by anthracyclines. | | | This suggested that alcohol metabolites were important determinants of negative inotropism induced by anthracyclines. |
|
http://www.nature.com/bjp/journal/v134/n6/full/0704369a.html
|
|
| |
| | Late Effects: Heart |
| | Note: Linda Z points out one more heart problem related to treatment, ant that is the potential for developing sudden and life threatening arrhythmias because of scarring to the clump of nerves that are responsible for monitoring the rhythm of the heart. | | | Chemotherapy (specifically, the anthracyclines) and radiation can affect the heart years after treatment. | | | It's difficult for us to hold our kids back, especially when they seem very healthy and have a lot of physical endurance, and when they have had echocardiograms at the end of treatment which indicate that they do not have heart damage. |
|
http://www.acor.org/ped-onc/survivors/cardio.html
|
|
| |
| | Better Breast Cancer Therapy: Making Anthracyclines More Effective |
| | TERRY P. MAMOUNAS, MD: There's very convincing evidence that adjuvant chemotherapy in general will improve survival, and certainly that's including evidence that anthracycline-containing therapy is actually more effective than non-anthracycline-containing therapy. | | | KATHLEEN PRITCHARD, MD: I think the biggest window of difference is for the cardiac effects, where you can give almost twice as much, milligram per milligram, epirubicin as you can adriamycin before seeing the same kind of cardiac problems. | | | Better Breast Cancer Therapy: Making Anthracyclines More Effective |
|
http://www.hairlossadvisor.com/hairlossadvisor/1883.htm
|
|
| |
| | National Cancer Institute - Clinical Trials (PDQ®) |
| | Adjuvant anthracycline based therapy followed by relapse after 6 months treated with anthracycline/taxane combination as first line therapy or first line anthracycline based therapy and second line taxane based therapy for advanced or metastatic disease | | | Any adjuvant therapy other than anthracycline based therapy followed by first line anthracycline based therapy and second line taxane based therapy for advanced or metastatic disease | | | Adjuvant anthracycline based therapy followed by relapse within 6 months treated with first line taxane based therapy for advanced or metastatic disease |
|
http://www.nci.nih.gov/clinicaltrials/EORTC-16001
|
|
| |
| | Anthracycline Cardiotoxicity Needs Tracking for Years |
| | The clinicians said that the anthracycline semiquinone doxorubicin and the stereo-isomer epirubicin "are among the most effective and widely used anti-cancer drugs with particularly widespread use in the therapy of breast cancer, sarcomas and leukemia. | | | Remember we are NOT Doctors and have NO medical training. | | | Assessment of left ventricular function during or immediately after patients are treated with anthracycline cancer chemotherapy is unlikely to predict cardiotoxicity. |
|
http://www.annieappleseedproject.org/ancarneedtra.html
|
|
| |
| | Biological Barriers Contributing to Anthracycline Resistance |
| | An understanding of the biological mechanisms contributing to treatment failure with current regimens is necessary to develop more effective therapeutic approaches for acute leukemia. | | | Correlative studies suggest that some of the recognized mechanisms have prognostic relevance and, therefore, may contribute to clinical drug resistance. | | | Other variables possibly influencing response to this type of treatment approach include the prevalence of P-gp-positive cases in each treatment arm, the ability to achieve and sustain effective chemomodulator blood levels and the presence of non- MDR mechanisms affecting anthracycline resistance. |
|
http://www.meds.com/leukemia/trends/mon_pt3.html
|
|
| |
| | Bundesverband Niedergelassener Kardiologen e.V. (BNK) |
| | Although the causes of anthracycline-induced cardiotoxicity are probably many, a large body of evidence points to free-radical-mediated myocyte damage. | | | Age and female gender seem to have an important role in the anthracycline cardiotoxicity. | | | Depending on the sensitivity of the method employed, the proportion of hearts found to be damaged has varied widely. |
|
http://www.bnk.de/herz/en/1887_3020.htm
|
|
| |
| | Bis-anthracyclines with high activity against doxorubicin resistant tumors (US5874412) |
| | Booser D.J. and Hortobgyi G.N., "Anthracycline Antibiotics in Cancer Therapy. | | | Young et al., "The Anthracycline Antineoplastic Drugs," N. Engl. | | | Potmesil et al., "Structure and Biological Activity of N-Substituted Anthracyclines: Correlation with Drug-DNA Topoisomerase II Interaction," Experimental Therapeutics, Proceedings of AACR, 28:262, Mar. 1987, Abstract 1034. |
|
http://www.delphion.com/details?pn=US05874412__&language=en
|
|
| |
| | A unified definition of clinical anthracycline resistance breast cancer |
| | These results indicate that strictly defined anthracycline resistance as defined in Groups 1 and 2 is associated with resistance to many other cytotoxic drugs. | | | The purpose of the study was to determine the response rates (RR) and duration to second- and third-line chemotherapy programmes in patients with anthracycline-resistant breast cancer, utilizing various definitions of anthracycline resistance. | | | This was a retrospective analysis performed on 1335 patients with metastatic breast cancer who participated in consecutive clinical trials of first line, anthracycline-containing combination chemotherapy (ACCC) at the University of Texas MD Anderson Cancer Center between July 1973 and April 1980. |
|
http://www.nature.com/bjc/journal/v82/n3/abs/6690958a.html
|
|
| |
| | News - Oral Capecitabine Improves Quality of Life in Patients With Anthracycline- And Taxane-Pretreated Metastatic ... |
| | "Given the clear preference among patients with advanced cancer for oral therapy, capecitabine merits consideration as 'standard therapy' for anthracycline and taxane-pretreated patients," they suggest. | | | The oral fluoropyrimidine, capecitabine, is the only approved treatment for patients with anthracycline- and taxane-pretreated metastatic breast cancer. | | | Oral capecitabine appears to be effective and well tolerated in patients with anthracycline- and taxane-pretreated metastatic breast cancer, and it also improves quality of life (QOL), according to the findings of a new multicentre phase 2 study. |
|
http://docguide.com/news/content.nsf/news/8525697700573E1885256E3B0036A497
|
|
| |
| | Localization of Anthracycline Accumulation in Sensitive... |
| | KEY WORDS: drug resistance, urothelial cancer, anthracyclines, high resolution fluorescence image analysis, confocal microscopy. | | | Anthracyclines exhibit natural fluorescence; therefore, the techniques used for detection were high-resolution fluorescence image analysis and confocal microscopy. | | | Our aim was to investigate anthracycline uptake in sensitive and resistant urothelial cancer cell lines and to manipulate uptake by resistant cells. |
|
http://www.cancerprev.org/Journal/Issues/20/6/160
|
|
| |
| | News - Three Anthracycline Regimens Comparable in Older Patients with Acute Myeloid Leukaemia |
| | They also found that the complete remission rate for the first 113 analysable patients, who did not participate in the priming study and started induction therapy 3 to 5 days earlier than those who did, was significantly higher (50% versus 38%; p=0.03). | | | Three anthracycline regimens appear to be comparable in efficacy and toxicity in treating older patients with acute myeloid leukaemia (AML). | | | Three Anthracycline Regimens Comparable in Older Patients with Acute Myeloid Leukaemia |
|
http://docguide.com/news/content.nsf/news/8525697700573E1885256DAF0033E150
|
|
| |
| | News - Anthracycline-Based Neoadjuvant Chemotherapy May Offer Survival Benefit When Prescribed in Combination With ... |
| | In this retrospective trial, Dr R. Kim, and colleagues, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan, evaluated the response and survival benefits of combining primary neoadjuvant systemic therapy including an anthracycline-based regimen with adjuvant chemotherapy in 25 patients with stage IIIB, locally advanced breast cancer. | | | The 5-year survival rate was 69.7% in patients treated with neoadjuvant chemotherapy compared with 77.8% in patients treated with adjuvant anthracycline-based chemotherapy. | | | Primary neoadjuvant systemic chemotherapy regimens including anthracyclines may offer a potential survival benefit when administered with adjuvant chemotherapy since they can decrease local recurrences and distant metastases in patients with locally advanced stage III breast cancer, write Japanese researchers. |
|
http://www.docguide.com/news/content.nsf/news/8DE595A1D1A070EE85256EBE00645C09
|
|
| |
| | ASCO - Basic Search - Anthracycline based chemotherapy decreases amplification status of Her-2/neu and topoisomerase II ... |
| | Methods: 122 previously untreated patients who had LABC and who had received neoadjuvant, anthracycline-based therapy were studied. | | | Our data provide plausible mechanism for diminished trastuzumab efficacy in anthracycline pretreated patients and provide molecular rationale for administration of trastuzumab as the first-line treatment in patients with Her-2/neu amplified LABC. | | | Background: Coamplification of Her-2/neu (H) and topoisomerase II alpha (T), was associated with favorable local response to anthracycline-based therapy in locally advanced breast cancer (LABC). |
|
http://www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-003154,00.asp
|
|
| |
| | Anthracycline-induced cardiotoxicity: echocardiographic monitoring |
| | Parameters that were followed include: fractional shortering, end sistolic and end diastolic left ventricle internal diameter, trans-mitral flow velocity, isovolumetric relaxation time, deceleration time. | | | Children Cancer Study Group suggests that all patients expected to received anthracyclines should have baseline cardiac evaluation with ECG and echocardiogram; an echocardiogram shuold be obtain before every other subsequent course of anthracycline below a cumulative dose of 300 mg/m | | | The anthracycline antibiotics cause both acute and long-term cumulative toxis effects on the heart. |
|
http://www.sicped.it/sicp2003/p97.htm
|
|
| |
| | Anthracyclines |
| | Most of the information I found about this group of drugs was specific for daunorubicin or doxorubicin. | | | References allude to the same side effects in each anthracycline drug, some more, some less, and different anthracyclines work better against different cancers. | | | Long-term anthracycline therapy and a cumulative dose of about 550 mg/square meter (!) causes an unusual heart toxicity. |
|
http://www.pfeist.net/ALL/anth.html
|
|
| |
| | HealthScout-Consumer Health News, Information and Resources Updated Daily--Protecting Kids' Hearts After Cancer - ... |
| | Lipshultz says, "Twenty-five years later, we see very alarming rates of increased death related to heart problems in these children." The problem is Adriamycin is very effective in treating the cancer but poses risks to the heart. | | | This type of chemotherapy is called anthracycline, which includes well-known agents that are used in many pediatric and adult cancers including Adriamycin. | | | DANGERS OF CHEMO: Dr. Lipshultz says more than 50 percent of children are treated with a life-saving form of chemotherapy that can damage the heart. |
|
http://www.healthscout.com/news/1/8009727/main.html
|
|
| |
| | ASCO - Browse by Meeting - Serum Troponin T as an Indicator of Anthracycline Cardiotoxicity in Adults. |
| | Follow-up after completion of anthracycline therapy was five months (median, range 1-11). | | | The number of anthracycline containing treatment cycles the patients had received before cTnT became elevated was two (median, range 0-7). | | | Cardiomyocyte toxicity can already be observed at low cumulative doses, and cTnT may serve as an early parameter to identify patients who are at increased risk of cardiac dysfunction after high cumulative anthracycline doses. |
|
http://www.asco.org/ac/1,1003,_12-002636-00_18-0010-00_19-001552,00.asp
|
|
| |
| | ASCO - Browse by Meeting - Myocardial expression of HER2 and HER4 in anthracycline-pretreated breast cancer patients. |
| | Many data indicate an important role of HER2 and its preferred cardiac heterodimerisation partner HER4 in mediating essential myocytes survival pathways. | | | Conclusions: This study shows that an anthracycline treatment does not result in changes of the HER2 or HER4 expression levels nor in amplification of the HER2 gene in the myocardium as suspected to probably underlie the onset of heart failure in anthracycline pretreated patients receiving Trastzumab therapy. | | | A phase 2 study of oxaliplatin (O) – capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes. |
|
http://www.asco.org/ac/1,1003,_12-002702-00_18-0026-00_19-002810-00_30-001,00.asp
|
|
| |
| | CANCER MEDS |
| | Study Comments Open label multicenter randomized study of 511 patients of capecitabine plus docetaxel versus monotherapy with docetaxel | | | Specific Indication Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents | | | FDA Oncology Tools Approval Summary for capecitabine for Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents |
|
http://www.geocities.com/moonotter1/xeloda.html
|
|
| |
| | www.patientcenters.com -- Non-Hodgkin's Lymphoma Center |
| | "A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation" Journal of Clinical Oncology 6, no. 11 (1988): 1732-35. | | | The National Cancer Institute's PDQ State-of-the-Art Treatment Statements for Physicians on: Anxiety disorder, Constipation, impaction, and bowel obstruction, Depression, Fatigue, Lymphedema, Nausea and vomiting, Nutrition, Oral complications secondary to cancer therapy, Pain, Post-traumatic stress disorder, Pruritus, Radiation enteritis, Skin integrity changes secondary to cutaneous metastases, Sleep disorders. |
|
http://www.patientcenters.com/lymphoma/news/nhl41.html
|
|
| |
| | DARE abstract20021098 |
| | Details of the anthracycline therapy used in the included studies were incomplete. | | | The included studies were cohort studies that monitored patients from the start of the anthracycline treatment, cohort studies of patients who survived childhood cancer, and subgroups of these cohorts. | | | Studies of anthracycline therapy (doxorubicin, daunorubin or epirubicin) were eligible for inclusion. |
|
http://nhscrd.york.ac.uk/online/dare/20021098.htm
|
|
| |
| | Optimizing Docetaxel Tolerability in Anthracycline-Resistant Breast Cancer |
| | Major responses occurred in 16 of 25 patients with liver metastases, and in 10 of 21 patients classified as anthracycline resistant or refractory. | | | Four patients were anthracycline refractory, and 18 exhibited resistance to anthracyclines. | | | Dr. Nisticò reported findings in 55 advanced breast cancer patients, all of whom had a history of anthracycline therapy. |
|
http://www.cancernetwork.com/journals/oncnews/n9902sup2e.htm
|
|
| |
| | Scalp hypothermia for 3 hours reduces alopecia after anthracycline based chemotherapy. |
| | A wig was not required in 82% of the patients. | | | Introduction: Hair loss is one of the most disturbing side effects for patients with solid tumours receiving anthracycline based chemotherapy. | | | Compared to historic controls, adjuvant and palliative anthracycline based chemotherapy is feasible without relevant hair loss for the majority of patients. |
|
http://www.esmo.org/reference/abstracts00/psc/705.htm
|
|
| |
| | Taxotere®/Carboplatin Effective for Anthracycline-Resistant Advanced Breast Cancer |
| | However, some patients do not respond to initial therapy with anthracyclines or stop responding to anthracyclines following repeated cycles. | | | Patients resistant to anthracyclines have options including several chemotherapy agents that provide anti-cancer responses and researchers are comparing different therapies to determine optimal regimens. | | | This trial included 36 women who had either stopped responding to previous therapy with an anthracycline or had not responded to initial therapy containing an anthracycline. |
|
http://patient.cancerconsultants.com/breast_cancer_news.aspx?id=17299
|
|
| |
| | Men 10755 (antitumoral anthracycline) |
| | In preclinical trials it was found to be superior to currently-used anthracyclines in antitumoral therapy (58% of positive results versus 25% for Doxorubicin) and is also endowed with lower cardiotoxicity. |
|
http://www.menarini.com/english/ricerca_sviluppo/sabarubicin.htm
|
|
| |
| | Fast Track, Priority Review and Accelerated Approval |
| | Induction of remission in patients with acute promyelocytic leukemia (APL) who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens. | | | (clinical benefit subsequently established) Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents | | | For use in addition to surgery to prolong survival in patients with recurrent glioblastoma multiforme who qualify for surgery. |
|
http://www.accessdata.fda.gov/scripts/cder/onctools/Accel.cfm
|
|
| |
| | XELODA (capecitabine) Oral Chemotherapy Tablets – Home Page |
| | Breast Cancer Monotherapy: XELODA monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m | | | Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. |
|
http://www.xeloda.com
|
|
| |
| | PRO-Pharmaceuticals,inc. ( OUR TECHNOLOGY ) |
| | Adriamycin (doxorubicin; 14-hydroxydaunomycin), a conjugate of an anthracycline adriamycinone and a sugar daunosamiine, a cancer chemotherapy drug; | | | Epirubicin, an antitumor drug, containing an aminosugar linked to an anthracycline structure; | | | Aloin, a conjugate of aloe-emodin and glucose, a cathartic drug; |
|
http://www.pro-pharmaceuticals.com/our3_2_3.shtml
|
|
| |
| | Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer |
| | Thrombocytopenia in the mitomycin/vinblastine arm (7% of patients) and fluid retention (6% of patients) in the docetaxel arm were the main treatment-ending adverse events. | | | The overall response rate achieved with docetaxel (28%) was greater than that achieved by the combination regimen (13%) in a population of patients with a high proportion of true resistance (primary and secondary) to anthracyclines. | | | Not resistant-- patients with progression of metastatic disease at least 30 days after chemotherapy for metastatic breast cancer or exposure to previous anthracycline in an adjuvant and/or neoadjuvant setting, provided that further chemotherapy was given for advanced disease. |
|
http://www.cancernetwork.com/journals/oncology/doc306.htm
|
|
| |
| | Energy Citations Database (ECD) - Energy and Energy-Related Bibliographic Citations |
| | Anthracycline compounds are useful agents in cancer therapy.^Major toxicities include mucositis and other gastrointestinal complications, myelodepression and cardiotoxicity.^With the current multimodal cancer therapy, anthracycline toxicities may be potentiated by radiation treatment or other chemotherapeutic agents.^The choice of anthracycline, drug combination, and drug schedule should be carefully evaluated to minimize toxicity. | | | Availability information may be found in the Availability, Publisher, Research Organization, Resource Relation and/or Author (affiliation information) fields and/or via the "Full-text Availability" link. | | | Energy Citations Database (ECD) Document #5096407 - Anthracycline toxicity |
|
http://www.osti.gov/energycitations/product.biblio.jsp?osti_id=5096407
|
|
| |
| | DRUG-DNA INTERCALATION © |
| | This would shed some light on the possibility of the target ring-D modified anthracycline ( 4) (R=H) intercalating with DNA and thereby test anticancer activity and intercalation theory. | | | Indeed, an anthracycline lacking the hydroxyl group at C-9 on the right side of the ring-A is devoid of anticancer activity. | | | Several factors play a role in the stabilisation of the drug-DNA complex. |
|
http://www.jonathanpmiller.com/intercalation
|
|
| |
| | Acute myelogenous leukemia |
| | In all FAB subtypes except M3, the usual treatment includes cytarabine ( Ara-C) and an anthracycline (such as daunorubicin or idarubicin). | | | Complete remission is obtained in about 70 percent of newly diagnosed adults. |
|
http://www.sciencedaily.com/encyclopedia/acute_myelogenous_leukemia
|
|
|
